Cytiva to provide Arranta Bio “idea to injection” solutions for integrated manufacturing of mRNA products

Cytiva, a global life sciences leader, will provide its FlexFactory single-use manufacturing platform to Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) for use in manufacturing mRNA vaccines.

Arranta is adding 10 million USD on top of its 100 million USD investment into its new Watertown, MA facility to open a dedicated space for mRNA manufacturing, Lipid nanoparticle (LNP) formulation, and drug product filling.

Arranta is offering the first end-to-end platform for cGMP manufacturing of mRNA products. The new space is scheduled to open within six months and will include in-vitro transcription, mRNA purification, lipid nanoparticle (LNP) formulation, and aseptic filling with first GMP production in Q3 of 2022.

Mark Bamforth, Executive chair and CEO of Arranta, noted that “Arranta is offering mRNA developers something unique: an integrated suite of complementary services from a single provider. Cytiva’s solutions provide us with the flexibility and modularity to offer our customers tailored manufacturing. With the addition of Cytiva’s robotic aseptic filling solutions, we are truly an end-to-end, single point of contact CDMO, reducing overall complexity, cost, and time to the product innovators.”

Cytiva acquired the aseptic business from Canadian company Vanrx in early 2021. The purchase completed its biomanufacturing workflow, enabling the company to offer solutions from ‘idea to injection.’

Olivier Loeillot, Vice president of Bioprocess at Cytiva, says: “Our agreement with Arranta marks the first time our full range of solutions will be used in the manufacturing of mRNA.  We’ve developed our platform to work for a multitude of modalities beyond the traditional mAbs, such as cell and gene therapies, plasmid DNA, and now, mRNA. It’s exciting to support this next generation of therapies that will benefit patients globally and deliver on our company mission to advance and accelerate therapeutics.”

Arranta Bio Announces Completion of Sale of Florida Site and Progress on $150M Investment Plan to Expand Development and Commercial Manufacturing Services

WATERTOWN, Mass., Nov. 15, 2021 /PRNewswire/ — Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, today announced the completion of the sale of its process development and GMP clinical manufacturing site in Gainesville, Florida, to Inceptor Bio and the transfer of client programs and key technical employees to Arranta’s Watertown, MA facility.

“We are delighted that Inceptor Bio will build on the foundation that we established in Gainesville and wish them every success in developing life-saving cell therapy products,” said Mark Bamforth, executive chair and CEO at Arranta, “and we are thrilled to continue to build and expand Arranta’s commercial-ready manufacturing team in Massachusetts, the global hub for biosciences.”

Arranta’s Watertown facility now has a team of over 160 employees focused on supporting microbiome clients, establishing messenger RNA vaccine capabilities, and manufacturing critical starting materials.

Arranta has established a strong microbiome platform including proprietary media and cryopresevative formulations to maximize yields and enhance viability for live biopharmaceutical products that clients are testing in the clinic against a range of infectious, inflammatory, neurological, and oncology diseases.

In addition, Arranta is progressing the establishment of end-to-end mRNA capabilities that were announced recently and expects to begin laboratory-scale operations in January and to have starting materials, mRNA, lipid nanoparticle formulation, and a robotic sterile fill line installed in Watertown by the end of Q2 2022.

Arranta recently received permitting approval to progress the first build-out phase of laboratory and GMP capacity establishment at a second commercial-ready site in Boxborough, MA, which will be completed by mid-2022. “With over 200,000 ftof facilities in Watertown and Boxborough and over $150 million committed to building state-of-the-art facilities, Arranta has the capacity to respond to client needs for complex biopharmaceutical products that will change the lives of patients,”  said David Stevens, President and COO at Arranta.

Inceptor Bio Announces Agreement to Acquire Gainesville, FL GMP Facility And Transfer Operating Team From Arranta Bio To Accelerate Cell Therapies To Cure Cancer

RALEIGH, N.C., Oct. 27, 2021  — Inceptor Bio (“Inceptor”), today announced an agreement with Arranta Bio (“Arranta”) for the acquisition of a 29,000 ft2 process development and GMP clinical manufacturing facility and the transfer of a core operating team to establish cell therapy processes and clinical supply for Inceptor Bio’s planned oncology clinical trials.

Inceptor Bio’s Advanced Manufacturing Platform (AMP+) will be based at the new facility in Gainesville, FL, that will be developed as a state-of-the-art cell and gene therapy GMP facility to deliver Inceptor Bio’s programs.

“We are thrilled to welcome the experienced, talented operating team from Arranta and look forward to establishing cell therapy GMP clinical manufacturing as a key strategic capability. This acquisition accelerates Inceptor Bio’s path to the clinic for our CAR-T, CAR-M and CAR-NK programs with our lead CAR-T candidate scheduled for IND in early 2023,” said Shailesh Maingi, Founder and CEO of Inceptor Bio.

Inceptor Bio is developing multiple next-generation cell therapy platforms to address difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment (TME). Inceptor Bio currently has three cell therapy technologies: a CAR-T platform with a novel co-stimulatory technology, a CAR-M platform using macrophages with enhanced phagocytic capabilities, and a CAR-NK platform.

Arranta is a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers. Arranta has invested in building the capabilities at the Gainesville, FL site and expanded the team over the last two years. “After conducting a strategic review, we concluded that the early clinical supply for clients from our Gainesville facility could be supported by our experienced team and accommodated in the over 200,000 ft2 of facilities that Arranta has in Massachusetts” said Mark Bamforth, Executive Chair and CEO at Arranta. “We are delighted that some of the technical team will transfer to Massachusetts, leaving a highly capable GMP operating team in place for Inceptor. We wish them every success in their critical mission.”

Arranta Bio Announces First End-to-End Manufacturing for mRNA Vaccines in its Commercial-ready GMP Facility

Watertown, Massachusetts (USA) – September 23, 2021: Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, today announced plans to establish contract manufacturing capacity for messenger RNA (mRNA) vaccines. Arranta will offer the first end-to-end platform for full integration of cGMP manufacturing of critical raw materials, in-vitro transcription, mRNA purification, LNP formulation and sterile fill/finish all within its Watertown, MA facility. Arranta intends to support product innovators using an mRNA platform to develop vaccines, for example, vaccines targeting infectious diseases, as well as therapeutic vaccines, such as those targeting cancer.

mRNA vaccines are a relatively new class of vaccines. Prophylactic vaccines have been recently validated with the successful commercialization of COVID-19 vaccines, while therapeutic immuno-oncology focused vaccines offer significant promise to cancer patients.  This latter class of mRNA vaccines works by encoding single or multiple tumor antigens that stimulate a specific immune response and produce anti-tumoral immunity.

“Arranta Bio is building a team with deep expertise in analytical and process development, and GMP manufacturing to support clients in this cutting-edge sector that is poised to transform vaccines for infectious diseases and cancer treatments” said Mark Bamforth, Executive Chair and CEO of Arranta. “We are delighted to be able to expand access to provide best-in-class mRNA capacity with the first end-to-end platform in a single facility. Arranta’s leadership team has a track-record of establishing commercial facilities and has supported successful FDA approvals for dozens of biopharmaceutical products and are committed to support mRNA vaccine innovators.”

In 2020, Arranta completed the built-out and commissioning of an 80,000ft² commercial-ready facility in Watertown, MA, with Grade C (ISO 7) clean rooms, which are suitable for the production of mRNA, lipid nanoparticle formulation, and sterile fill/finish into vials within isolator technology. Arranta will have drug substance process development and formulation development capacity in place by the end of 2021 in existing laboratories and GMP clinical manufacturing by early 2022 from existing clean rooms which are already qualified. Integrated isolator technology will be installed and operational in the second half of 2022 to complete the end-to-end platform. Additional suites are available to meet client needs, including dedicated custom capacity options.

Arranta has an established bacterial manufacturing platform for live bacterial pharmaceuticals (LBPs) targeting the human microbiome, and for fermented starting materials for use in advanced mRNA vaccines.

Arranta has deep experience and continues to invest in capabilities, following an initial $100M spend in the fit-out of world class, commercial-ready facilities and in building a deeply experienced team. Arranta is proud to be a leading CDMO focused on supporting the supply needs of these varied innovator companies.

About Arranta Bio

Founded in 2019, Arranta Bio is a visionary contract development and manufacturing organization (CDMO) that partners with companies seeking to develop and manufacture complex biological drugs and innovative therapies. Our dedicated team, state-of-the-art facilities, and unparalleled resources are crucial for advancing products from development to commercial launch. Arranta Bio continues to expand capacity and development and manufacturing services across multiple sites with technology platforms designed to meet the evolving demands of our clients and partners. Additional information about Arranta Bio is available at www.arrantabio.com

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector.  With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at www.ampersandcapital.com.

Vibalogics, Lincoln Property Company and Arranta Bio donate to the Boxborough Conservation Trust

BOXBOROUGH, MASSACHUSETTS, UNITED STATES, June 4, 2021 Vibalogics, a global virotherapy contract development and manufacturing organization (CDMO), Arranta Bio (“Arranta”), the leading microbiome CDMO, along with Lincoln Property Company (LPC) today made a significant donation to the Boxborough Conservation Trust (BCT) a private, nonprofit 501(c)(3) organization founded in 1997 to preserve and protect Boxborough Massachusetts’s rural character and natural resources.

Arranta and Vibalogics are both tenants of LPC and each company is developing the former Cisco Systems Inc. facility at 1414 Massachusetts Ave into a state-of-the-art cGMP biopharmaceutical manufacturing facility. Both organizations embrace working in harmony with the environment, their neighbors and with the town staff and boards.

The Boxborough site is being developed in phases, and work for Vibalogics has been approved by the planning board. The total investment in the facility is expected to exceed $200 million and employ around 400 employees between the two companies. The facilities for both companies are designed to flexibly support clients, including dedicated lab and biomanufacturing capacity that can support commercial manufacturing and supply life-changing medicine.

Scott Brown, Executive Vice President at LPC stated, “We are delighted to be able to work with two progressive biopharmaceutical manufacturing companies tackling highly prevalent diseases including cancer, dementia, diabetes, autism and other highly prevalent diseases. The 1414 facility has the potential to provide breakthrough treatments of the future.”

Mark Bamforth, Executive Chairman and CEO of Arranta stated, “In 2019 we developed our company values, central to which is Arranta Bio Cares focusing on community outreach, diversity and inclusion, and environmental impact. Therefore we are delighted to be able to support the BCT in their role in protecting the Boxborough environment, common areas and providing advice to property owners.”
Tom Hochuli, CEO of Vibalogics states, We look forward to delivering a positive impact to mutually benefit both our business and the local community for many years to come.” “Both our mission and core ENABLE values are central to everything we do as a company, we are therefore focused on not only being recognized as a great place to work, but also as being a good neighbor in the town and community where we operate.”

About LPC
Lincoln Property Company, founded in 1965, is a privately-held national commercial real estate company involved in real estate investment, development, property management and leasing worldwide. Lincoln has offices in all major markets of the U.S. and throughout Europe. Lincoln’s cumulative development efforts have produced over 130 million square feet of commercial space. For more information on Lincoln Property Company’s Boston office, visit: www.LPCBoston.com.

About Arranta
Founded in 2019, Arranta Bio is a contract development and manufacturing organization (CDMO) specifically established to serve companies seeking to develop and commercialize therapies targeting the human microbiome. Arranta’s roots go back to 2009 through Captozyme™ which became a part of Arranta in November 2019. Arranta’s experienced team has worked with and developed processes for over 145 different species spanning 90 different genera of live biotherapeutics. Headed by a management team and technical experts with a proven track record in both process development and contract manufacturing from fermentation to lyophilization and encapsulation of live biopharmaceuticals, Arranta Bio offers the knowledge and resources necessary to help clients develop and manufacture promising new microbiome therapies and plasmids to meet the needs of patients from early clinical to commercial supply. Additional information about Arranta Bio is available at www.arrantabio.com, or contact: bd@arrantabio.com.

About Vibalogics
Vibalogics is a global contract development and manufacturing organization (CDMO) located in Cuxhaven, Germany and Boxborough, Massachusetts, USA providing process development and GMP manufacturing services. Founded in 2002, the company is recognized as a leading service provider within the live biologics industry, specializing in the manufacture of oncolytic virus, viral vector vaccine and viral vector gene therapy products. For more information, please visit www.vibalogics.com, or contact:  experts@vibalogics.com.

Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and closes Series B Equity Financing

Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced the addition of a 130,000-square-feet facility in Boxborough, Massachusetts, to complement its existing facilities in Watertown, Massachusetts and Gainesville, Florida, bringing the total manufacturing capacity at Arranta to over 230,000 square feet. Arranta closed an oversubscribed Series B equity financing from its current investors to fund the expansion.

The Boxborough site will be developed in phases, and work for the first two phases has begun; the total investment in Boxborough is expected to exceed $150 million and employ over 250 employees, with the first phases of construction underway and start-up of GMP suites expected early in 2022. The facility is designed to flexibly support clients, including dedicated lab and GMP capacity that can support commercial products or a pipeline of products for a client. The GMP manufacturing suites are designed to be flexible in scale, size and design to accommodate client and product-specific processing requirements for both drug substance and finished drug product. Initial multi-client capacity will include up to multiple 2,000L scale single-use bioreactors for anaerobic bacteria or 1,000L scale single-use fermenters for aerobic bacteria and fully automated drug product manufacturing. Additionally, Arranta plans to add secondary packaging and labeling capabilities at the facility.  

“We are excited by the recent clinical results that demonstrate the potential of microbiome therapies to positively impact patient outcomes in a broad range of diseases,” Mark Bamforth, Executive Chair and CEO of Arranta Bio, said. “This new facility demonstrates Arranta’s commitment to support the increasing maturity of the microbiome live biotherapeutic product sector by offering innovators best-in-class development and GMP manufacturing capabilities that support their programs from lab to market.”

“In discussions with leading microbiome innovators, we see strong interest in dedicated client capacity and new manufacturing capabilities to meet the commercial supply needs of this sector,” David Stevens, President and COO of Arranta Bio, said. “We are continuing to expand our organization, adding experience and skills to meet clients’ needs, and expect to have over 200 on our team by the end of 2021 and up to 500 employees once fully staffed.”

Arranta invested more than $100 million in 2020 to expand its process development and early clinical GMP supply capacity at its campus in Gainesville, and established a state-of-the-art, multi-product, commercial-ready manufacturing facility in Watertown. The Watertown facility was completed at the end of 2020 and is now being commissioned to supply live biotherapeutic products (LBPs) to microbiome innovator companies.

“We are delighted to have the continued support and enthusiasm of our existing shareholders, who over-subscribed in a Series B equity financing round, which will be used to fund the initial build-out and start-up of the Boxborough facility and to fuel additional long-term growth for Arranta,” said Steven Favaloro, CFO at Arranta Bio. The amount raised was not disclosed.

About 400 companies are actively exploring the linkage between diseases and the microbiome – millions of bacteria, fungi, protozoa, and viruses that live inside and on the human body – in order to identify therapeutic targets. Scientists have called the microbiome the second genome. In fact, the number of genes in the microbes making up one person’s microbiome is estimated to be at least 200 times the number in the human genome.

In the past decade, the industry has experienced a rapid acceleration in scientific understanding of the composition and functions of gut microbiota. Arranta is proud to be the leading CDMO focused on supporting the supply needs of these innovator companies.

Arranta Bio Announces Key Promotions and Addition to its Board of Directors

Arranta Bio, the leading microbiome contract development and manufacturing organization (CDMO), announced the promotion of David Stevens to President and Chief Operating Officer (COO) and the appointment of Iain Baird to Arranta Bio’s Board of Directors.

“I am delighted to announce the promotion of David Stevens and to share that Iain Baird is joining Arranta Bio’s Board. I look forward to continuing to work with them as we build the leading, best-in-class microbiome CDMO,” said Mark Bamforth, Executive Chairman and CEO of Arranta Bio.

Mr. Stevens joined Arranta Bio at its inception as COO. His expanded role now includes business development and commercial operations, Quality, and site operations functions at both Arranta Bio’s Gainesville, FL location for process development and early clinical manufacturing and the Watertown, MA location for late-clinical and commercial manufacturing of live biopharmaceutical products (LBPs) for microbiome product pioneers. The organization has now grown to 130 employees and occupies over 100,000 ft2 of space dedicated to supporting this sector.

Mr. Stevens brings more than 20 years of broad international operations and commercial experience in the CRO and CDMO sectors. He was formerly the Senior Vice President & Head of AMRI’s Drug Product business unit where he had P&L responsibility for sales and operations. During his tenure, he led the division through a period of significant growth and capacity expansion. Prior to leading the division, Mr. Stevens held a number of senior leadership roles at AMRI, including Vice President, Sales & Marketing and General Manager of a sterile dosage form development and GMP manufacturing facility.

Prior to AMRI, Mr. Stevens held leadership roles of increasing responsibility at Aptuit, including site leadership and operational excellence He started his career with Inveresk and Charles River Laboratories.

Mr. Stevens holds an MBA in strategy, finance and marketing from the University of Edinburgh and an undergraduate degree in Business from Edinburgh.

Mr. Baird is a founder of Arranta Bio and was instrumental in building the foundation of the company.  He now joins the Board of Directors. Mr. Baird runs his own consultancy business and has worked with the founders/CEO’s of six companies over the past 10 years, starting companies developing new biological pharmaceutical products and CDMOs providing services to the sector, including OSO BioPharmaceuticals Manufacturing, CANbridge Life Sciences, Gallus Biopharmaceuticals, Brammer Bio, and Vibalogics US.

Prior to that, Mr. Baird worked 20 years in the pharmaceutical and chemical industries. He started work for ICI, which later became Zeneca and then AstraZeneca. In 2006, he was one of the principles that established Avecia Vaccines, during which he led the Chemistry Manufacturing and Control groups in the development of vaccines against anthrax and plague.

Since 2010, Mr. Baird has been an independent consultant assisting clients in the development of their clinical products and has been involved in filing 16 IND’s, three successful BLA applications and three successful NDA applications, as well as remediating a product placed on CMC hold by the FDA. Iain has supported clients through numerous FDA, EMA and international regulatory inspections.

Mr. Baird holds a BEng in mechanical and electrical engineering from Robert Gordons University.

About 400 companies are actively exploring the linkage between diseases and the Marvelous Microbiome – millions of bacteria, fungi, protozoa and viruses that live inside and on the human body – in order to identify therapeutic targets. Scientists have called the microbiome the second genome; in fact, the number of genes in the microbes making up one person’s microbiome is estimated to be at least 200 times the number in the human genome.

In the past decade, the industry has experienced a rapid acceleration in scientific understanding of the composition and functions of gut microbiota. Arranta Bio is proud to be the leading CDMO focused on supporting the supply needs of these innovator companies.

Arranta Bio Announces Pledge to Diversity, Inclusion and Sustainability with CSR Program

Arranta Bio recently announced the launch of a corporate social responsibility (CSR) program, Arranta Bio Cares, and appointed Susan Surabian as the initiative’s leader. 

As a champion of diversity and inclusion from its inception, the company’s CSR program will continue to prioritize efforts promoting Arranta Bio Cares’ core pillars. Firstly, the company is striving for a welcoming, diverse culture that fosters racial, social and gender equality. Next, we are strengthening local communities in MA and FL by encouraging employees to volunteer and donate. Finally, we encourage choosing vendors and partners that align with the company’s vision for sustainability.  

Mark Bamforth, President and CEO at Arranta said “It is too easy to feel helpless in the face of systemic racism and disparity in our society. As a result, it is vital that every organization commits to tack these issues by opening doors for those from minority and disadvantaged communities to forge a fulfilling, life-long career in the life sciences. We are committed to living the values that will make a meaningful, sustained change at Arranta.”

CSR Program Leadership

As an early leader of community outreach and advocate of inclusion at Arranta Bio, Susan was a natural choice to lead the CSR Program, Arranta Bio Cares. Susan’s beliefs extend past her workplace and permeate every facet of her life. 

“Without a parallel evolution of each individuals’ responsible behaviors, CSR program  corporate strategies cannot be a reality,” Susan said. “For the last 10 years, I’ve focused on community outreach and volunteering with a goal to spread kindness and equality with steady perseverance. I’ve practiced this in a variety of ways: Firstly, I am antiracist and stand up for diversity and inclusion by participating in events, signing petitions, and partnering with school systems; Secondly, I focus on protecting our environment by purchasing sustainable products, clothing, and cutting back on personal waste. Finally, I choose organic foods and partner with organizations that can both make an impact and educate others about how our food choices affect our bodies and planet.” 

Susan believes that consistency in the workplace and in employees’ everyday lives is key to improving the future of the life sciences industry and beyond.

Arranta has donated to local pantries and community help organizations through the pandemic, supported STEM education organizations in FL and MA, and worked with Life Science Cares and Year Up to make an impact in our communities. 

An employee-led advocacy team is assisting Susan in planning, community outreach, and diversity and inclusion activities. Arranta Bio Cares will have additional executive support from Lana Gladstein, Chief Legal Officer and general counsel. 

To learn more about Arranta Bio Cares and our partner organizations, visit arrantabio.com/cares. 

Arranta Bio Named Finalist for Gainesville Chamber Life Science Company of the Year

Concluding a year of growth, challenge and agility, we’re proud to announce that Arranta Bio has been a named Life Science Company of the Year finalist in the Gainesville Chamber of Commerce 2020 Business Awards.

This honor marks the second year Arranta, which acquired Gainesville-based biotechnology CDMO Captozyme in November 2019, has been chosen for a top placement in the annual business awards. Arranta Bio was included in this category with Ology Bioservices Inc.

Finalists for the 2020 Business Awards were announced on November 19, with 37 local organizations representing 13 categories. Finalists were chosen after a panel of impartial judges carefully reviewed and graded each application.

Arranta Bio Announces Mechanical Completion of Commercial-Ready Capacity for advanced biologics

Watertown, MA (USA) – September 28, 2020: Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced the mechanical completion of GMP suites at its Watertown, MA commercial-ready facility.

Arranta is investing more than $100M in 2020 to establish a state of the art, multi-product, commercial-ready manufacturing facility that will supply live biotherapeutic products (LBPs) to microbiome innovator companies. The Watertown facility has been designed to the highest specifications for advanced biologics production.

 “We are grateful to the Arranta team and to our construction management partner, DC Beane and Associates Construction Company, who specializes in the construction and development of life science facilities, and the numerous sub-contractors who have supported Arranta and worked through the pandemic in a safe and efficient manner to keep our commercial-ready manufacturing facility build-out on schedule. This is a remarkable accomplishment that will enable Arranta to supply vital products to patients in need and provide more than 200 new product development, manufacturing and operations jobs,” Mark Bamforth, President and CEO of Arranta Bio, said.

Arranta is also expanding process development, and GMP capacity at its early-clinical supply facility in Gainesville, FL. Learn more about overcoming the construction management challenges during the pandemic by registering for a webinar moderated by Arranta’s co-founder, Iain Baird, taking place on Wednesday Sept 30th at 10am EST at https://kineticos.com/building-a-cdmo-facility-during-covid

About 200 companies are actively exploring the linkage between diseases and the microbiome – millions of bacteria, fungi, protozoa and viruses that live inside and on the human body – in order to identify therapeutic targets. Scientists have called the microbiome the second genome; in fact, the number of genes in the microbes making up one person’s microbiome is estimated to be at least 200 times the number in the human genome. 

In the past decade, the industry has experienced a rapid acceleration in scientific understanding of the composition and functions of gut microbiota. Arranta is proud to be the leading CDMO focused on supporting the supply needs of these innovator companies.

About Arranta Bio

Founded in 2019, Arranta Bio is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize therapies targeting the human microbiome. In November 2019, Arranta Bio acquired Captozyme™ – the leader in process development and clinical contract manufacturing for microbiome pioneers – whose experienced team has worked with and developed processes for over 135 different species spanning 85 different genera of live biotherapeutics since 2009. Headed by a management team and technical experts with a proven track record in both process development and contract manufacturing through fermentation to lyophilization and encapsulation of live biopharmaceuticals, Arranta Bio offers the knowledge and resources necessary to help clients develop and manufacture promising new microbiome therapies and plasmids to meet the needs of patients. Additional information about Arranta Bio is available at www.arrantabio.com.  

Arranta Bio Media contact: 

Guy Tiene
That’s Nice LLC
T: +1 212 366 4455
E: guy@thatsnice.com

Arranta Bio Services contact: 
info@arrantabio.com